{
    "clinical_study": {
        "@rank": "3155", 
        "arm_group": [
            {
                "arm_group_label": "Fimasartan 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "Take one capsule filled with a Fimasartan 30 mg in the every morning"
            }, 
            {
                "arm_group_label": "Valsartan 80 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Take one capsule filled with a Valsartan 80 mg in the every morning"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to Evaluate the Antihypertensive efficacy of Fimasartan 30 mg\n      during 24 hours in Patients with Mild to Moderate Essential Hypertension"
        }, 
        "brief_title": "A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects aged 20 to 70 years\n\n          2. Essential hypertension subjects who are measured more 135/85 mmHg of average\n             Diastolic Blood pressure (DBP) and Systolic Blood pressure (SBP) measured by ABP\n             monitor at baseline visit(day 0)\n\n          3. Subjects who agreed to participate in this study and submitted the written informed\n             consent\n\n          4. Subjects who considered to understand this study, be cooperative, and able to be\n             followed-up whole of the study period\n\n        Exclusion Criteria:\n\n          1. Severe hypertension patients; more 180 mmHg of mean sitting SBP and/or more 110 mmHg\n             of mean sitting DBP measured as an office Blood pressure (BP), before Randomization\n             (Screening visit, Placebo run-in visit, Pre-Baseline visit, Baseline visit)\n\n          2. Patients with difference of office BP at selected one arm over DBP 10 mmHg and/or SBP\n             20 mmHg at screening visit\n\n          3. Patients with secondary hypertension\n\n          4. Patients with symptomatic orthostatic hypotension\n\n          5. Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c > 9%,\n             increased regimen of oral hypoglycemic agent, using insulin at baseline visit)\n\n          6. Patients with severe heart disease, ischemic heart disease within 6 months,\n             peripheral vascular disease, Percutaneous Transluminal Coronary Angiography (PTCA),\n             Coronary Artery Bypass Graft (CABG)\n\n          7. Patients with significant ventricular tachycardia, atrial fibrillation, atrial\n             flutter or other significant arrhythmia\n\n          8. Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary\n             artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral\n             valve disease\n\n          9. Patients with severe cerebrovascular disease within 6 months\n\n         10. Patients with known severe or malignancy retinopathy within 6 months\n\n         11. Patients with wasting disease, autoimmune disease, connective tissue disease\n\n         12. Patients with significant investigations - abnormal renal function (Creatinine more\n             1.5 times than upper limit of normal), abnormal liver function (Aspartate\n             Transaminase(AST), Alanine Transaminase(ALT) more 2 times than upper normal)\n\n         13. Patients with surgical or medical disease which is able to be affect to absorption,\n             distribution, metabolism, excretion\n\n         14. Patients with hereditary disorders of galactose intolerance, Lapp lactase deficiency\n             or glucose-galactose malabsorption\n\n         15. Patients with significant investigations - Hypokalemia(Less than 3.5mmol/L),\n             Hyperkalemia(exceeded 5.5mmol/L)\n\n         16. Patients with depletion of body fluid or sodium ion not able to correct\n\n         17. Patients with suspected or history of drug or alcohol abuse within the past two years\n\n         18. Childbearing, breast-feeding women and female who plan to become pregnancy or have a\n             possibility of pregnancy but don't prevent conception with acknowledged methods\n\n         19. Patients with any chronic inflammation disease needed to chronic inflammation therapy\n\n         20. Patients with hepatitis type B or type C and carriers\n\n         21. Patients with laboratory test results indicating clinically significant abnormal\n             results\n\n         22. Patients receiving medication that can affect blood pressure\n\n         23. Patients with history of allergic reaction to any angiotensin II antagonist\n\n         24. Patients with the medical histories of malignant tumor within 5years, except local\n             basal cell carcinoma of the skin\n\n         25. Patients who took investigational drug within 12 weeks from screening visit or is\n             going on the progress of other clinical trial\n\n         26. Subject who are judged unsuitable to participate in this study by investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878201", 
            "org_study_id": "A657-BR-CT-L201"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fimasartan 30 mg", 
                "description": "Fimasartan 30 mg", 
                "intervention_name": "Fimasartan", 
                "intervention_type": "Drug", 
                "other_name": "Kanarb"
            }, 
            {
                "arm_group_label": "Valsartan 80 mg", 
                "description": "Valsartan 80 mg", 
                "intervention_name": "Valsartan", 
                "intervention_type": "Drug", 
                "other_name": "Diovan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Valsartan", 
                "Antihypertensive Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fimasartan", 
            "24 hours ABP monitoring(ABPM)", 
            "antihypertension"
        ], 
        "lastchanged_date": "June 12, 2013", 
        "location": {
            "contact": {
                "email": "ohbhmed@snu.ac.kr", 
                "last_name": "Byung-Hee Oh, Professor", 
                "phone": "82-2-2072-3345"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Valsartan 80 Mg-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension", 
        "other_outcome": [
            {
                "description": "Adverse evnt(AE)s are collected as a safety measure. All AEs are arranged based on severity, relevance to the investigational drug and serious adverse event each.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "about 10~11weeks from placebo run-in visit"
            }, 
            {
                "description": "Adverse changes in laboratory test results are collected as a safety measure. As a continuous data group for each test visit, adverse changes in laboratory test results present descriptive statistics (mean, standard deviation, minimum, maximum, etc.)", 
                "measure": "Adverse changes in laboratory test results", 
                "safety_issue": "Yes", 
                "time_frame": "about 10~11weeks from screening visit"
            }, 
            {
                "description": "Adverse changes in ECG are collected as a safety measure. As a categorical data, adverse changes in ECG present frequency and percentage for each category.", 
                "measure": "Adverse changes in electrocardiography(ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "about 10~11weeks from screening visit"
            }
        ], 
        "overall_contact": {
            "email": "eunj0408@boryung.co.kr", 
            "last_name": "EunJeong Jeon, Manager", 
            "phone": "82-2-708-8062"
        }, 
        "overall_contact_backup": {
            "email": "ssuran@boryung.co.kr", 
            "last_name": "Suran Ryu, Assistant", 
            "phone": "82-2-708-8143"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Byung-He Oh, professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministy of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the difference of Mean Systolic Blood Pressure during 24 hours at 8 weeks from baseline visit", 
            "measure": "Mean Systolic Blood Pressure during 24 hours", 
            "safety_issue": "No", 
            "time_frame": "8 weeks from baseline visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878201"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To compare the difference of Mean Diastolic Blood Pressure during 24 hours at 8 weeks from baseline visit", 
                "measure": "Mean Diastolic Blood Pressure during 24 hours", 
                "safety_issue": "No", 
                "time_frame": "8 weeks from baseline visit"
            }, 
            {
                "description": "To compare the difference of Diastolic Blood pressure and Systolic Blood pressure during daytime or nighttime at 8 weeks from baseline visit", 
                "measure": "Mean Diastolic Blood pressure and Systolic Blood pressure during daytime or nighttime", 
                "safety_issue": "No", 
                "time_frame": "8 weeks from baseline visit"
            }, 
            {
                "description": "To compare the difference of Sitting Diastolic Blood pressure and Systolic Blood pressure at 8 weeks from baseline visit", 
                "measure": "Sitting Diastolic Blood pressure and Systolic Blood pressure", 
                "safety_issue": "No", 
                "time_frame": "8 weeks from baseline visit"
            }, 
            {
                "description": "Trough-to-peak ratio of systolic blood pressure and diastolic blood pressure measured by ABP(Ambulatory Blood Pressure) monitor", 
                "measure": "Trough-to-peak ratio", 
                "safety_issue": "No", 
                "time_frame": "8 weeks from baseline visit"
            }, 
            {
                "description": "Smoothness index of systolic blood pressure and diastolic blood pressure measured by ABP monitor", 
                "measure": "Smoothness index", 
                "safety_issue": "No", 
                "time_frame": "8 weeks from baseline visit"
            }
        ], 
        "source": "Boryung Pharmaceutical Co., Ltd", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Seoul National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Asan Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Seoul National University Bundang Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kyungpook National University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chonnam National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Inje University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Boryung Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}